During the past decade, Azienda Ospedaliera Papa Giovanni XXIII conducted 194 clinical trials. In the 10-year time frame, 194 clinical trials started and 56 clinical trials were completed, i.e. on average, 28.9% percent of trials that started reached the finish line to date. In the past 5 years, 92 clinical trials started and 43 clinical trials were completed. i.e. 46.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Ospedaliera Papa Giovanni XXIII" #1 sponsor was "Hoffmann-La Roche" with 15 trials, followed by "Gilead Sciences" with 12 trials sponsored, "Mario Negri Institute for Pharmacological Research" with 12 trials sponsored, "Amgen" with 11 trials sponsored and "Janssen Research & Development, LLC" with 11 trials sponsored. Other sponsors include 198 different institutions and companies that sponsored additional 116 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliera Papa Giovanni XXIII" #1 collaborator was "Papa Giovanni XXIII Hospital" with 5 trials as a collaborator, "AbbVie" with 4 trials as a collaborator, "Eli Lilly and Company" with 4 trials as a collaborator, "Istituto Di Ricerche Farmacologiche Mario Negri" with 4 trials as a collaborator and "Clinical Research Technology S.r.l." with 3 trials as a collaborator. Other collaborators include 214 different institutions and companies that were collaborators in the rest 201 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliera Papa Giovanni XXIII" are "Multiple Myeloma" (11 trials), "Breast Cancer" (10 trials), "Melanoma" (9 trials), "Heart Failure" (8 trials) and "HIV-1 Infection" (7 trials). Many other conditions were trialed in "Azienda Ospedaliera Papa Giovanni XXIII" in a lesser frequency.

Most popular intervention types in "Azienda Ospedaliera Papa Giovanni XXIII" are "Drug" (181 trials), "Other" (29 trials), "Device" (20 trials), "Biological" (15 trials) and "Procedure" (13 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (35 trials), "Nivolumab" (10 trials), "Dexamethasone" (8 trials), "Rituximab" (8 trials) and "Atezolizumab" (6 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Ospedaliera Papa Giovanni XXIII" are 250 trials for "All" genders, 11 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Azienda Ospedaliera Papa Giovanni XXIII". undefined are not yet recruiting, 56 are recruiting, 37 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 114 completed trials in Azienda Ospedaliera Papa Giovanni XXIII, undefined suspended trials, and 27 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Ospedaliera Papa Giovanni XXIII, 18 "Phase 1" clinical trials were conducted, 70 "Phase 2" clinical trials and 104 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 11 trials, and there were also 17 trials that are defined as “Not Applicable".

Azienda Ospedaliera Papa Giovanni XXIII has several departments that took part in Clinical trials: "Asst Papa Giovanni XXIII; Oncologia Medica" - 17 trials, "ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla" - 4 trials, "Hospital "Azienda Ospedaliera Ospedali Riuniti di Bergamo" Unit of Neprology and Dialysis" - 2 trials, "U.O. Nefrologia e Dialisi" - 6 trials, "Cardiovascular Department Ospedali Riuniti di Bergamo" - 2 trials, "Asst Papa Giovanni Xxiii - Cardiologia 1" - 2 trials